ライフサイエンスコーパス: pulmonary tuberculosis

1 rom 17 Ugandans treated for drug-susceptible pulmonary tuberculosis.

2 sociated with an increased susceptibility to pulmonary tuberculosis.

3 n Themis(I23N) mice causes susceptibility to pulmonary tuberculosis.

4 ning regimen for treating rifampin-sensitive pulmonary tuberculosis.

5 atients with newly diagnosed sputum-positive pulmonary tuberculosis.

6 of two of these regimens in a mouse model of pulmonary tuberculosis.

7 ed their critical role in protection against pulmonary tuberculosis.

8 l for PMN-driven destructive inflammation in pulmonary tuberculosis.

9 h treatment of uncomplicated, smear-positive pulmonary tuberculosis.

10 n 370 patients with microbiologically proven pulmonary tuberculosis.

11 r suspected drug-resistant or HIV-associated pulmonary tuberculosis.

12 tiveness of corticosteroids in patients with pulmonary tuberculosis.

13 school in the United Kingdom presented with pulmonary tuberculosis.

14 ust to exclusion of individuals experiencing pulmonary tuberculosis.

15 g PD-1 and its ligand(s) among patients with pulmonary tuberculosis.

16 ied 41 eligible trials, 18 of which assessed pulmonary tuberculosis.

17 r the response to treatment in patients with pulmonary tuberculosis.

18 ciated with increased mortality and incident pulmonary tuberculosis.

19 icroscopy for diagnosis of culture-confirmed pulmonary tuberculosis.

20 ing host T-cell function among patients with pulmonary tuberculosis.

21 ity for all forms of tuberculosis, including pulmonary tuberculosis.

22 ates with bacteria in lungs of patients with pulmonary tuberculosis.

23 om HIV-negative patients suspected of having pulmonary tuberculosis.

24 urable in exhaled breath in individuals with pulmonary tuberculosis.

25 eolar lavage cells from patients with active pulmonary tuberculosis.

26 es that had either tuberculous meningitis or pulmonary tuberculosis.

27 occur at extrapulmonary sites without active pulmonary tuberculosis.

28 is (EPTB) has increased relative to cases of pulmonary tuberculosis.

29 ents receiving intensive-phase treatment for pulmonary tuberculosis.

30 fferences in mortality attributed to HIV and pulmonary tuberculosis.

31 immunity in the outbred guinea pig model of pulmonary tuberculosis.

32 ed human lung expirations from patients with pulmonary tuberculosis.

33 y in vivo, especially its role in control of pulmonary tuberculosis.

34 chromosome 1, which controls progression of pulmonary tuberculosis.

35 an unusually severe index case of infectious pulmonary tuberculosis.

36 of-care assay as a screening tool for active pulmonary tuberculosis.

37 ailed study of West African populations with pulmonary tuberculosis.

38 berculosis infection will progress to active pulmonary tuberculosis.

39 nostic performance of laboratory testing for pulmonary tuberculosis.

40 y BCG vaccination in the guinea pig model of pulmonary tuberculosis.

41 d-fast bacilli in sputum samples to diagnose pulmonary tuberculosis.

42 therapy is recommended for the treatment of pulmonary tuberculosis.

43 n the highly susceptible guinea pig model of pulmonary tuberculosis.

44 s the earliest phase of primary infection in pulmonary tuberculosis.

45 ere still necessary to definitively diagnose pulmonary tuberculosis.

46 nduced by these vaccines in a mouse model of pulmonary tuberculosis.

47 haran Africa is not as well described as for pulmonary tuberculosis.

48 nexposed control subjects, and patients with pulmonary tuberculosis.

49 ed BCG has inefficient effectiveness against pulmonary tuberculosis.

50 osed cases), and bacteriologically confirmed pulmonary tuberculosis.

51 there is no effective vaccine against adult pulmonary tuberculosis.

52 V (CD4 cell counts </=125 cells per muL) and pulmonary tuberculosis.

53 specimens in 3640 children investigated for pulmonary tuberculosis.

54 25 (43%) children had pulmonary tuberculosis, 24 (41%) had extrapulmonary tube

55 Among 236 patients with pulmonary tuberculosis, 59 (25%) had isoniazid resistanc

56 One hundred patients with pulmonary tuberculosis (65% human immunodeficiency virus

57 Air pollution and pulmonary tuberculosis: a nested case-control study amon

58 or risk factor for the development of active pulmonary tuberculosis, although the immunological mecha

59 smear positive or culture positive, or both) pulmonary tuberculosis among adults (aged >/=15 years) i

60 We identified 18 trials reporting pulmonary tuberculosis and 6 reporting miliary or mening

61 Among 200 patients with pulmonary tuberculosis and 88 controls, FENO was lower f

62 cted an association study in Morocco between pulmonary tuberculosis and a panel of single-nucleotide

63 t study of HIV-infected patients with active pulmonary tuberculosis and baseline CD4 counts </=125 ce

64 us (HIV) positive and negative patients with pulmonary tuberculosis and controls.

65 ases including pneumonia with pleural fluid, pulmonary tuberculosis and healthy people as controls.

66 In 2011-14, pulmonary tuberculosis and HIV were responsible for 84.9

67 Reductions in pulmonary tuberculosis and HIV-related mortality account

68 significant association between progressive pulmonary tuberculosis and homozygosity for HLA-DQ beta5

69 Cachexia is a hallmark of pulmonary tuberculosis and is associated with poor progn

70 backgrounds reproduce a clinical spectrum of pulmonary tuberculosis and may be used to more accuratel

71 assay with GLA samples for the detection of pulmonary tuberculosis and MDR tuberculosis in new paedi

72 D sufficiency may decrease the incidence of pulmonary tuberculosis and other infectious diseases.

73 culosis, but variable efficacy against adult pulmonary tuberculosis and other mycobacterial diseases.

74 sociated with higher efficacy of BCG against pulmonary tuberculosis and possibly against miliary and

75 ks of ART and early mortality in adults with pulmonary tuberculosis and pre-ART CD4 counts </= 125 ce

76 No particular link was found between pulmonary tuberculosis and pulmonary embolism, or betwee

77 RIF (Xpert) with microscopy for detection of pulmonary tuberculosis and rifampicin resistance in chil

78 otection similar to BCG in a murine model of pulmonary tuberculosis and suggest that Sin85B-induced p

79 . tuberculosis strains in the mouse model of pulmonary tuberculosis and suggest that strain-specific

80 in immunocompetent humans the development of pulmonary tuberculosis and the failure of the existing v

81 criteria in children with culture-confirmed pulmonary tuberculosis and those in whom tuberculosis ha

82 ociated with both tuberculous meningitis and pulmonary tuberculosis and were strongest with a recessi

83 8.1%) were HIV-infected, 40% had concomitant pulmonary tuberculosis, and 14.7% died within 12 months

84 c testing for latent tuberculosis infection, pulmonary tuberculosis, and extrapulmonary tuberculosis

85 the incidence of microbiologically confirmed pulmonary tuberculosis, and new cases of pulmonary tuber

86 hold contacts (HHCs) of patients with active pulmonary tuberculosis are exposed aerogenically to Myco

87 United States, individuals with presumptive pulmonary tuberculosis are placed in airborne infection

88 rated from the cough of patients with active pulmonary tuberculosis are the source of MTB infection.

89 cell subsets that appear in the lung during pulmonary tuberculosis are unknown.

90 s exposed to Mtb rapidly progressed to acute pulmonary tuberculosis as indicated by worsening clinica

91 ssifiable including 21 (21.0%) with definite pulmonary tuberculosis, as they did not meet the NIH cri

92 enrolled close contacts of individuals with pulmonary tuberculosis, assessed LTBI status, and determ

93 easures were made of 21 men and 9 women with pulmonary tuberculosis at baseline and after 1 and 6 mo

94 In Papua, we measured FENO in patients with pulmonary tuberculosis at baseline and serially over 6 m

95 n 28 of 29 (97%) cases with culture-positive pulmonary tuberculosis at bedaquiline initiation.

96 8 controls, FENO was lower for patients with pulmonary tuberculosis at diagnosis (geometric mean FENO

97 st 18 years with microbiologically confirmed pulmonary tuberculosis at Old Mulago Hospital (Kampala,

98 <25 years) with an odds ratio of developing pulmonary tuberculosis at rs897200 for GG vs AG/AA subje

99 n of this technique for routine diagnosis of pulmonary tuberculosis at this time.

100 m of patients with microscopy smear-positive pulmonary tuberculosis-at eight sites in South Africa an

101 m, MA, USA) for screening for HIV-associated pulmonary tuberculosis before antiretroviral therapy (AR

102 In the guinea pig model of pulmonary tuberculosis, boosting BCG-immunized animals o

103 stimate VE against all tuberculosis and just pulmonary tuberculosis by time since vaccination, adjust

104 first evidence relating arsenic exposure to pulmonary tuberculosis, by estimating mortality rate rat

105 ed protective responses in a murine model of pulmonary tuberculosis, C57BL/6 mice were vaccinated wit

106 dinal cohort of household contacts (HHCs) of pulmonary tuberculosis case patients in Lima, Peru.

107 , a patient with microbiologically confirmed pulmonary tuberculosis (Case 2).

108 Of 12 culture-confirmed pulmonary tuberculosis cases identified among children w

109 A substantial proportion of active pulmonary tuberculosis cases in countries where tubercul

110 tified 8 (42.1%) of the 19 culture-confirmed pulmonary tuberculosis cases that were identified throug

111 Twenty-seven (3.0%) culture-confirmed pulmonary tuberculosis cases were identified among 906 c

112 ion (p=0.00048); the percentage of clustered pulmonary tuberculosis cases, which decreased by 62.6% f

113 e and 101 (0.3%) bacteriologically confirmed pulmonary tuberculosis cases.

114 were measured in 45 patients with confirmed pulmonary tuberculosis (cases), 47 tuberculin skin test

115 stered BCG confers robust protection against pulmonary tuberculosis challenge.

116 wian adults with microbiologically confirmed pulmonary tuberculosis, clinical and laboratory paramete

117 e of sputum Mtb clearance over 16 wk in this pulmonary tuberculosis cohort.

118 ay samples from HIV-1-infected patients with pulmonary tuberculosis compared with those with non-tube

119 nificantly greater association with incident pulmonary tuberculosis, compared with vitamin D sufficie

120 Inclusion patients were those with pulmonary tuberculosis confirmed by sputum smear microsc

121 tion of tests for the diagnosis of childhood pulmonary tuberculosis (CPTB) is complicated by the abse

122 men were also elevated but with fewer excess pulmonary tuberculosis deaths (359 among men and 95 amon

123 ntly with tofacitinib than with placebo, and pulmonary tuberculosis developed in two patients in the

124 older than 15 years of age) who had incident pulmonary tuberculosis diagnosed at any of 106 public he

125 nucleic acid amplification testing (MTD) for pulmonary tuberculosis disease diagnosis in the United S

126 ntent-to-treat trial in 199 individuals with pulmonary tuberculosis disease in Tbilisi, Georgia.

127 ere household contacts of adults with active pulmonary tuberculosis disease.

128 tation improves outcomes in individuals with pulmonary tuberculosis disease.

129 cohort study of inpatients with presumptive pulmonary tuberculosis enrolled adults with 1 or more sp

130 rease the yield of microscopy for diagnosing pulmonary tuberculosis, even in high-HIV-prevalence sett

131 ousehold as an active case of smear-positive pulmonary tuberculosis exposed to M. africanum progress

132 ntified cases of microbiologically confirmed pulmonary tuberculosis from 2004 to 2012 from the Nation

133 s with primary and secondary cases of active pulmonary tuberculosis from the southern region (Afghani

134 ture media, from participants with suspected pulmonary tuberculosis from the United States, Brazil, a

135 l blood lymphocytes from human patients with pulmonary tuberculosis, from asymptomatic individuals wi

136 ted tuberculosis (group 3); 49 patients with pulmonary tuberculosis (group 4); and 48 healthy control

137 netic epidemiological evidence suggests that pulmonary tuberculosis has a strong human genetic compon

138 estimates, the prevalence of smear-positive pulmonary tuberculosis has decreased by 26.4% (from 231

139 he prevalence of bacteriologically confirmed pulmonary tuberculosis has increased by 17.8% (from 365

140 iagnosis of culture-proven, drug-susceptible pulmonary tuberculosis immediately prior to treatment an

141 Among patients with pulmonary tuberculosis, impaired pulmonary NO bioavailab

142 who had successfully completed treatment for pulmonary tuberculosis in 1995, to determine the rate an

143 t of reported patients with suspected active pulmonary tuberculosis in 2008-2010 from Georgia, Hawaii

144 d consecutively from patients with suspected pulmonary tuberculosis in a tertiary-care hospital in Ri

145 to detect and treat all infectious cases of pulmonary tuberculosis in a timely fashion, allowing con

146 come was the prevalence of culture-confirmed pulmonary tuberculosis in adults (>/=18 years), defined

147 ed retrospectively a cohort of patients with pulmonary tuberculosis in Birmingham, United Kingdom (Ja

148 ecutive children hospitalized with suspected pulmonary tuberculosis in Cape Town, South Africa, who w

149 fers better sensitivity for the diagnosis of pulmonary tuberculosis in children and its scale-up will

150 ia for standardized diagnostic categories of pulmonary tuberculosis in children have not been validat

151 Rapid and accurate diagnosis of pulmonary tuberculosis in children remains challenging b

152 e and specific method for rapid diagnosis of pulmonary tuberculosis in children who cannot produce sp

153 compared with microscopy in the diagnosis of pulmonary tuberculosis in children.

154 he most widely available diagnostic test for pulmonary tuberculosis in countries with a high burden o

155 ositive, rifampin-sensitive, newly diagnosed pulmonary tuberculosis in five sub-Saharan African count

156 We monitored the course of pulmonary tuberculosis in guinea pigs and observed four

157 Pulmonary tuberculosis in guinea pigs is an extremely us

158 Pulmonary tuberculosis in guinea pigs is similar to the

159 mains the optimal sample type for diagnosing pulmonary tuberculosis in HIV-negative patients with the

160 locus sst1 that controls the progression of pulmonary tuberculosis in immunocompetent hosts.

161 tamin D in adults with sputum smear-positive pulmonary tuberculosis in London, UK.

162 ted incidence of bacteriologically confirmed pulmonary tuberculosis in migrants screened before entry

163 Placing inpatients with presumed active pulmonary tuberculosis in respiratory isolation pending

164 the incidence of microbiologically confirmed pulmonary tuberculosis in South Africa had declined by 2

165 amples from 2,406 individuals with suspected pulmonary tuberculosis in South Africa were tested by Xp

166 ould improve the assessment of the burden of pulmonary tuberculosis in South Africa.

167 ecome activated during the early response to pulmonary tuberculosis in the mouse model and are a sour

168 We assessed the prevalence of pulmonary tuberculosis in the Xinjiang province, China,

169 s in other parts of China, the prevalence of pulmonary tuberculosis in Xinjiang remains high.

170 ets that examined clinical cohorts of active pulmonary tuberculosis infection in whole blood.

171 C, human immunodeficiency virus, and active pulmonary tuberculosis is considered.

172 performance of laboratory tests to diagnose pulmonary tuberculosis is dependent on the quality of th

173 Active pulmonary tuberculosis is difficult to diagnose and trea

174 Isolation of patients suspected for pulmonary tuberculosis is guided by serial sputum smears

175 A hallmark of pulmonary tuberculosis is the formation of macrophage-ri

176 m tuberculosis (MTB), the causative agent of pulmonary tuberculosis, is difficult to eliminate by ant

177 e current standard care for drug-susceptible pulmonary tuberculosis, isoniazid, rifampicin, PZA, and

178 ct tracing of a teenager with smear-positive pulmonary tuberculosis matched 14 individuals, including

179 Development of a vaccine against pulmonary tuberculosis may require immunization strategi

180 their subsequent degranulation during acute pulmonary tuberculosis, may play a key role in the susce

181 Eight participants with active pulmonary tuberculosis (mean age, 48.1 years; age range,

182 ted circulating Ag85 levels in patients with pulmonary tuberculosis measured by anti-Ag85 complex or

183 In pulmonary tuberculosis, MMP-driven immunopathology gener

184 NKT cells were measured in subjects with pulmonary tuberculosis, MTB-exposed individuals, and hea

185 culture-positive patients treated for active pulmonary tuberculosis (n = 372) in San Francisco County

186 The new smear-positive pulmonary tuberculosis notification rate in 2011 in Xinj

187 al evaluation enrolled adults with suspected pulmonary tuberculosis, obtained three sputum samples fr

188 ve men, compared with incidence rates of new pulmonary tuberculosis of 3.7 cases per 100 PYAR (95% CI

189 ic in Montreal, Canada, for the detection of pulmonary tuberculosis on induced sputum samples, using

190 ciation was stronger among younger subjects (pulmonary tuberculosis onset <25 years) with an odds rat

191 (T-SPOT) among adults with suspected active pulmonary tuberculosis or patients with confirmed cases

192 dependently associated with the incidence of pulmonary tuberculosis (P < .001), severe anemia (P < .0

193 ia (P = 0.002), oral thrush (P = 0.007), and pulmonary tuberculosis (P < 0.001) but not change in CD4

194 ed sample, 6 STAT4 SNPs were associated with pulmonary tuberculosis (P = .0013-.01).

195 ptibility to tuberculosis in a cohort of 436 pulmonary tuberculosis patients and 107 healthy controls

196 study of children who were close contacts of pulmonary tuberculosis patients in Indonesia from August

197 Forty percent of the sera from pulmonary tuberculosis patients tested for anti-Eis anti

198 Ex vivo blood samples from 27 pulmonary tuberculosis patients were assayed at diagnosi

199 rent clinical forms of tuberculosis, such as pulmonary tuberculosis, pleural tuberculosis, and lymph

200 In each age group and sex, the pulmonary tuberculosis prevalence was higher in the 2010

201 rculosis (8,162 cases and 277,643 controls), pulmonary tuberculosis (PTB) and M. tuberculosis infecti

202 of adjunctive vitamin D in the treatment of pulmonary tuberculosis (PTB) are variously limited by sm

203 ert testing from 115 children with suspected pulmonary tuberculosis (PTB) detected 8/17 (47%) culture

204 that individuals who escaped mortality from pulmonary tuberculosis (PTB) during the European tubercu

205 ortion of participants with culture-positive pulmonary tuberculosis (PTB) initiated on appropriate TB

206 A rapid diagnosis of pediatric pulmonary tuberculosis (PTB) using Xpert MTB/RIF (Mycoba

207 of the response, in patients with miliary or pulmonary tuberculosis (PTB)--have been reported.

208 filum terminale of the spinal cord); and (2) pulmonary tuberculosis (PTB).

209 n immunodeficiency virus (HIV) infection and pulmonary tuberculosis (PTB).

210 d the development of new approaches to treat pulmonary tuberculosis (PTB).

211 ned against sera from patients infected with pulmonary tuberculosis (PTB).

212 olation (AII) of inpatients with presumptive pulmonary tuberculosis (PTB).

213 Recurrent pulmonary tuberculosis rates >2 years after the first ep

214 Adults with pulmonary tuberculosis received standard 6-month therapy

215 6-year-old HIV-seronegative patient with XDR pulmonary tuberculosis refractory to medical therapy.

216 ART service were systematically screened for pulmonary tuberculosis regardless of symptoms by testing

217 med pulmonary tuberculosis, and new cases of pulmonary tuberculosis registered for treatment, nationa

218 Of the 184 cases of pulmonary tuberculosis reported during the study period,

219 in mouse models of neuroinflammation and of pulmonary tuberculosis, respectively.

220 re treatment from Gambians and Ugandans with pulmonary tuberculosis, revealed by positive results of

221 This supports the hypothesis that pulmonary tuberculosis sequesters MTB in a protected env

222 cal end point was the earliest occurrence of pulmonary tuberculosis, severe bacterial infection, a Wo

223 ween fractional exhale NO (FENO) and initial pulmonary tuberculosis severity, change during treatment

224 e of PCR for the diagnosis of smear-negative pulmonary tuberculosis (SPT) and to identify factors tha

225 acid-fast bacillus (AFB) smears to rule out pulmonary tuberculosis, sputum AFB smear and culture res

226 y similar to rifampin in human subjects with pulmonary tuberculosis, suggesting that it should underg

227 s with the ones from the 2010 China national pulmonary tuberculosis survey and the ones from a provin

228 irst, a patient presenting with 2-3 weeks of pulmonary tuberculosis symptoms (Case 1); and second, a

229 tic accuracy study, we recruited adults with pulmonary tuberculosis symptoms presenting at primary he

230 Mycobacterium tuberculosis causes pulmonary tuberculosis (TB) and claims 1.8 million huma

231 Coexistence of pulmonary tuberculosis (TB) and lung cancer in clinic po

232 Although studies identified signatures for pulmonary tuberculosis (TB) and transcripts that predict

233 ical consequences of IL-10 production during pulmonary tuberculosis (TB) are currently unknown, altho

234 Pulmonary tuberculosis (TB) can present with polymorphon

235 All active pulmonary tuberculosis (TB) cases newly diagnosed betwee

236 e gene (env) in HIV-1-infected patients with pulmonary tuberculosis (TB) compared to patients with HI

237 nfectious aerosols produced by patients with pulmonary tuberculosis (TB) has never been directly meas

238 etection of anti-CCP in patients with active pulmonary tuberculosis (TB) has recently been reported.

239 agents associated with presumptive clinical pulmonary tuberculosis (TB) in Nigeria and evaluated the

240 Opportunistic infections such as pulmonary tuberculosis (TB) increase local HIV-1 replica

241 Treatment failure after therapy of pulmonary tuberculosis (TB) infections is an important c

242 Pulmonary tuberculosis (TB) is characterized by oxidativ

243 Protective immunity against pulmonary tuberculosis (TB) is characterized by the form

244 Mycobacterium tuberculosis in patients with pulmonary tuberculosis (TB) is considered the most impor

245 A hallmark of pulmonary tuberculosis (TB) is the formation of granulom

246 om HIV-negative, smear- and culture-positive pulmonary tuberculosis (TB) patients for the presence of

247 ut the United States for all cases of active pulmonary tuberculosis (TB) to identify secondary cases

248 Patients with pulmonary tuberculosis (TB) underwent a standard evaluat

249 Diagnosis of pulmonary tuberculosis (TB) usually includes laboratory

250 utum smear supports treatment decisions with pulmonary tuberculosis (TB), but smear sensitivity for M

251 tuberculosis (MTb) is the causative agent of pulmonary tuberculosis (TB).

252 e of B cells in host defense against primary pulmonary tuberculosis (TB).

253 egulated in alveolar macrophages (AM) during pulmonary tuberculosis (TB).

254 st commonly used laboratory test to diagnose pulmonary tuberculosis (TB).

255 lood mononuclear cells from individuals with pulmonary tuberculosis than in both MTB-exposed subjects

256 A sensitivity analysis in pulmonary tuberculosis that excluded trials with high po

257 by BCG in the stringent guinea pig model of pulmonary tuberculosis, the "gold standard" for testing

258 forms of tuberculosis but not against adult pulmonary tuberculosis, the most common and contagious f

259 t, in human subjects, previously treated for pulmonary tuberculosis, the MTB-containing CD271(+) BM-M

260 ol trials (RCTs) that reported on first-line pulmonary tuberculosis therapy between June 2008 and Mar

261 intermittent dosing schedules in first-line pulmonary tuberculosis therapy.

262 m 755 HIV-uninfected adults with presumptive pulmonary tuberculosis to measure IgG antibody responses

263 riptional profiles in pulmonary sarcoidosis, pulmonary tuberculosis, to community acquired pneumonia

264 tine vs rifampin during the first 8 weeks of pulmonary tuberculosis treatment.

265 imicrobial activity of daily rifapentine for pulmonary tuberculosis treatment.

266 VE against pulmonary tuberculosis up to 9 years (excluding tubercul

267 fied in pretreatment sputum of patients with pulmonary tuberculosis using FDA microscopy, culture, an

268 e meta-regression indicated efficacy against pulmonary tuberculosis varied according to 3 characteris

269 iated with different sites of infection (eg, pulmonary tuberculosis versus extrapulmonary tuberculosi

270 The weighted prevalence of smear-positive pulmonary tuberculosis was 170 (95% CI 103-233) per 100

271 00 people and of bacteriologically confirmed pulmonary tuberculosis was 430 (249-611) per 100 000 peo

272 onstudy attending physicians requested GA if pulmonary tuberculosis was clinically suspected.

273 Active pulmonary tuberculosis was diagnosed in the United State

274 CASE REPORT: A young woman with pulmonary tuberculosis was found to have disseminated tu

275 rn analysis, and expression in patients with pulmonary tuberculosis was localized by immunohistochemi

276 nts in whom acid-fast bacilli smear-positive pulmonary tuberculosis was newly diagnosed were randomiz

277 lts in whom smear-positive, drug-susceptible pulmonary tuberculosis was newly diagnosed.

278 Among 2140 patients in whom pulmonary tuberculosis was suspected, 799 (37%) were M.

279 pecimen from each person suspected of having pulmonary tuberculosis was tested by smear microscopy, d

280 as components of lymphoid neogenesis during pulmonary tuberculosis, we have identified ectopic germi

281 ing the highly demanding guinea pig model of pulmonary tuberculosis, we have investigated the feasibi

282 Adults with sputum smear-positive pulmonary tuberculosis were assigned rifapentine 10, 15,

283 lmonary tuberculosis relative to exclusively pulmonary tuberculosis were greater for Euro-American (a

284 Adults suffering from their first episode of pulmonary tuberculosis were identified in Kampala, Ugand

285 creened, 444 (28%) culture-positive cases of pulmonary tuberculosis were identified.

286 Adults with smear-positive pulmonary tuberculosis were randomized in a factorial de

287 d adults with newly diagnosed smear-positive pulmonary tuberculosis were randomized to receive a 3- o

288 t-naive, sputum smear-positive patients with pulmonary tuberculosis were randomized to receive combin

289 total, 531 adults with sputum smear-positive pulmonary tuberculosis were randomized to rifapentine 10

290 , rifampicin-sensitive, previously untreated pulmonary tuberculosis were randomly assigned in a 1:1:1

291 523 371 cases of microbiologically confirmed pulmonary tuberculosis were recorded nationally.

292 Patients with an initial episode of pulmonary tuberculosis were recruited in South Africa.

293 of the 41 trials (including 13 of those for pulmonary tuberculosis) were done before the introductio

294 rculosis transmission: the incidence rate of pulmonary tuberculosis, which decreased by 54.4% between

295 s aged 15 years or older of index cases with pulmonary tuberculosis who lived in desert shanty towns

296 patients receiving antimicrobial therapy for pulmonary tuberculosis who were randomized to receive ad

297 atment-naive patients with drug-susceptible, pulmonary tuberculosis, who were randomly assigned by co

298 oroccan population support an association of pulmonary tuberculosis with STAT4 promoter-region polymo

299 with newly diagnosed, rifampicin-susceptible pulmonary tuberculosis, with and without HIV, enrolled i

300 otal role during the chronic/latent stage of pulmonary tuberculosis, with increased production playin